Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

Autor: Basil Sharrack, Ho Jin Kim, Rany A Aburashed, Thomas F. Scott, Andrew T. Chan, Carlo Pozzilli, Daniel Kantor, Richard A L Macdonell, Nadia Daizadeh, Dominique Dive, Samuel F. Hunter, Jan Lycke, Raed Alroughani, Darren P Baker, Heinz Wiendl, Sara Eichau, Luke Chung, Patrick Vermersch

Publikováno v: Neurology and Therapy
Hunter, Samuel F; Aburashed, Rany A; Alroughani, Raed; Chan, Andrew; Dive, Dominique; Eichau, Sara; Kantor, Daniel; Kim, Ho Jin; Lycke, Jan; Macdonell, Richard A L; Pozzilli, Carlo; Scott, Thomas; Sharrack, Basil; Wiendl, Heinz; Chung, Luke; Daizadeh, Nadia; Baker, Darren P; Vermersch, Patrick (2021). Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and therapy, 10(2), pp. 803-818. Springer 10.1007/s40120-021-00262-3

Introduction In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing–remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d7429be1a1b274c059ed9b671eb848
https://doi.org/10.1007/s40120-021-00262-3